Intraoperative search for neuroblastoma by MIBG and radioguided surgery with the gamma detector
Heij, H.A.; Rutgers, E.J.T.; de Kraker, J.; Vos, A.

Published in:
Medical and Pediatric Oncology

DOI:
10.1002/(SICI)1096-911X(199703)28:3<171::AID-MPO2>3.0.CO;2-G

Citation for published version (APA):
Intraoperative Search for Neuroblastoma by MIBG and Radioguided Surgery With the Gamma Detector

Hugo A. Heij, MD, ScD,1* Emiel J. Th Rutgers, MD, PhD,3 Jan de Kraker, MD, PhD,2 and Anton Vos, MD, ScD1

Administration of a tumour-seeking compound labeled with a low-energy isotope and intraoperative screening with the gamma probe (radioguided surgery, RGS) could be useful in reoperations for advanced neuroblastoma when the normal anatomy is altered. A pilot study was performed to test the feasibility of this technique. Five patients underwent six relaparotomies for recurrent stage III or IV neuroblastoma. All had been treated with intensive chemotherapy and/or metaiodobenzylguanidine (MIBG)-I131 with or without hyperbaric oxygen. Reoperation was performed to achieve near-total (greater than 95%) excision. In all instances, active tumour was seen on the preoperative MIBG scan. Before the operation, a tracer dose of MIBG-123 was given. At laparotomy, a search was made with the gamma probe for areas of increased activity. The gamma probe correctly identified active neuroblastoma tissue that was seen on the preoperative MIBG scan. There appeared to be a relationship between intensity of radioactivity and degree of maturation on histologic examination. This pilot study shows that RGS with MIBG and intraoperative use of the gamma probe is able to identify recurrent neuroblastoma. Whether this method is able to detect occult tumour and whether RGS will result in better outcome are the subjects of ongoing research.

Key words: neuroblastoma; radioguided surgery; metaiodobenzylguanidine (MIBG); gamma probe

INTRODUCTION

Reoperations for advanced neuroblastoma are indicated when the primary operation was irradical and postoperative chemotherapy has achieved sufficient reduction to allow successful reexcision. Alternatively, recurrence after initial macroscopic complete excision may necessitate reoperation. In these cases, it can be difficult to identify the exact localisation of tumour tissue because of altered anatomy. Administration of a tumour-seeking compound labeled with a low-energy isotope and intraoperative screening with a gamma probe (radioguided surgery, RGS) may be helpful. This technique has been applied successfully in colorectal and breast cancer using radioimmunolabeling [1–3]. In neuroblastoma, vital tumour cells are known to take up metaiodobenzylguanidine (MIBG). Radioactive MIBG, labeled with I131 or I123, is applied for diagnostic and therapeutic purposes [4,5].

A pilot study was performed to test the feasibility of using MIBG and the gamma probe for intraoperative localisation of neuroblastoma.

PATIENTS AND METHODS

Five patients underwent six relaparotomies for recurrent stage III or IV abdominal neuroblastoma (Table I). All had been treated with intensive chemotherapy and/or MIBG-I131 with or without hyperbaric oxygen. Reoperation was performed to achieve near-total (greater than 95%) excision. In all instances, active tumour was seen on the preoperative diagnostic MIBG scan. Ultrasound (US), computerized tomography (CT) scan, or magnetic resonance imaging (MRI) interpretations were hampered by the previous operations. Two days before surgery, a tracer dose of MIBG-I123 was given (185 mBq). After opening of the abdominal cavity and lysis of adhesions, a full exploration was performed, with the careful noting of all visible and/or palpable abnormalities. As a schematic aid, the abdomen was divided into four areas: the liver, the upper abdomen cranially from the transverse mesocolon, the lower abdomen bordered by the colon, and the pelvis below the promontory. Subsequently, the four parts of the abdomen were scanned consecutively with a hand-held gamma probe (Figs. 1 and 2; Neoprobe 1000; Neoprobe Corp., Columbus OH) packed in a sterile cover. In addition, any suspicious area is screened with the gamma probe. Background counts are recorded at the

Received 15 December 1995; accepted 10 May 1996.

1 Paediatric Surgical Centre Amsterdam; 2 Department of Paediatric Oncology, Emma Kinderziekenhuis/Kinder AMC; 3 Department of Surgery, The Netherlands Cancer Institute/Antoni van Leeuwenhoekhuis.

*Correspondence to: A. Vos, MD, Department of Paediatric Surgery, Emma Kinderziekenhuis AMC, Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands.
The highest mean counts were recorded. The exact size of the tumour was not always easy to estimate because of surrounding fibrosis.

Any clinically suspicious tissue—with or without elevated gamma counts—was excised. Tissues with elevated gamma counts without clinical suspicion were, whenever visible, biopsied for microscopic examination. After complete excision, the tumour bed was scanned for any residual activity.

The highest tumour counts related to the background normal tissue counts were recorded. Ex vivo tissue counts by a well counter were not performed. The exact amount of tumour-containing tissue was clinically difficult to assess as a result of surrounding fibrosis.

Minimal standard measurements were taken after the study protocol as shown in Figure 1. A tumour to background ratio of 2 or more was considered significant. For maximal reproducibility, it was important that the position of the probe was moved slowly over the examined tissue after squelching of the background radiation. Counts per 2 seconds were taken from the regions of interest and recorded on the protocol form.

**RESULTS**

The gamma probe correctly identified active neuroblastoma tissue that was seen on the preoperative MIBG scan. In Patient D, a persistent area of increased activity was seen near the right kidney without macroscopic abnormality. No tissue was excised in this area because that

---

**Fig. 1.** Protocol form.

**Fig. 2.** Neoprobe control unit.
TABLE I. Details of 6 relaparotomies in 5 patients

<table>
<thead>
<tr>
<th>Patient no.</th>
<th>age (y/m)</th>
<th>localisation</th>
<th>prim tumour</th>
<th>previous therapy</th>
</tr>
</thead>
<tbody>
<tr>
<td>A</td>
<td>3/11</td>
<td>Rt adrenal</td>
<td>MIBG</td>
<td>incompl res → CT + ABMT</td>
</tr>
<tr>
<td>B</td>
<td>3/8</td>
<td>Rt adrenal</td>
<td>CT</td>
<td>resection2 → MIBG</td>
</tr>
<tr>
<td>C</td>
<td>7/2</td>
<td>symp chain</td>
<td>CT</td>
<td>resection → MIBG</td>
</tr>
<tr>
<td>D</td>
<td>13/6</td>
<td>Rt symp chain</td>
<td>CT</td>
<td>resection</td>
</tr>
<tr>
<td>D</td>
<td>14/3</td>
<td>idem</td>
<td>CT</td>
<td>+ ABMT</td>
</tr>
<tr>
<td>E</td>
<td>7/0</td>
<td>Rt adrenal</td>
<td>MIBG</td>
<td>+ HBO</td>
</tr>
</tbody>
</table>

Legend:
CT = chemotherapy
ABMT = autologous bone marrow transplant
HBO = hyperbaric oxygen
MIBG = metaiodobenzylguanidine labeled with J-131

TABLE II. Intra-operative Tumour Activity and Histology in 4 Patients

<table>
<thead>
<tr>
<th>Pt no</th>
<th>Counts/2 sec over</th>
<th>T/NT ratio by probe</th>
<th>histology</th>
</tr>
</thead>
<tbody>
<tr>
<td>A</td>
<td>700  350</td>
<td>2</td>
<td>GN/GNB</td>
</tr>
<tr>
<td>B</td>
<td>1800 900</td>
<td>2</td>
<td>GNB</td>
</tr>
<tr>
<td>C</td>
<td>10 850 1800</td>
<td>6</td>
<td>GNB</td>
</tr>
<tr>
<td>D</td>
<td>4800 600</td>
<td>8</td>
<td>NB</td>
</tr>
</tbody>
</table>

Legend
NG = neuroblastoma
GNB = ganglioneuroblastoma
GN = ganglioneuroma
T/NT = tumour/no tumour.

DISCUSSION

This pilot study shows that it is possible to identify recurrent neuroblastoma with RGS with a tracer dose of $^{123}$I MIBG and intraoperative use of the gamma probe. In one patient, RGS-positive localisation without clinical evidence of tumour appeared to be the site of tumour recurrence, confirmed by relaparotomy 9 months later. During the initial laparotomy, a cyst-like structure in the right para-iliac region was also found. This cyst was RGS negative and turned out to be a lymphocele on histology after resection. This pilot experience also suggests that the intensity of radioactivity might be related to the degree of maturation of the tumour. Unfortunately, in this pilot study we did not perform ex vivo measurement of counts per gram excised tissue using a well counter. Therefore, no information was available about ex vivo tumour to nontumour counts/ratio, since counts per gram tissue can only be obtained ex vivo. Statistical analysis of the correlation between tumour size and counts was not performed in this study, but should be part of future protocols and related to the histology of the tumour. An inherent problem of recurrent neuroblastoma is distinguishing between fibrotic tissue and tumour. Inevitably, some amount of fibrous tissue will be included during excision, which makes it difficult to explore the correlation between tumour size and radioactivity as measured by the gamma probe. Considering our positive clinical experience with these five patients, further study is warranted. This RGS system with $^{123}$I MIBG might be helpful.

Concerning the safety of RGS using a tracer dose of $^{123}$I, it is clear that the use of $^{123}$I is not a radiation risk. The half-life of $^{123}$I is 13.2 hours, and this isotope is a low-energy inhibitor of 159 Kev. With the administration of a tracer dose of 185 mBeq, the gamma radiation exposure is extremely low, with minimal hazard for the patient, surgeon, or operating room personnel. Even the use of $^{123}$I (energy 35 Kev isotope with a half-life of 60.2 days) with larger doses does not produce any significant radiation risk [6].

CONCLUSIONS

From this limited experience, we can conclude that the method is both specific and sensitive for the detection of neuroblastoma. Ongoing research will be needed to analyze the relationship between radioactivity and histol-
ogy. It still has to be demonstrated that this technique has a beneficial effect on outcome.

REFERENCES


